British pharmaceutical company AstraZeneca applied on Tuesday for permission from the U.S. Food and Drug Administration to market a self-administered, needle-free nasal spray vaccine for annual flu protection.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.